Literature DB >> 1378313

Mediators of angiogenesis: the biological significance of basic fibroblast growth factor (bFGF)-heparin and heparan sulfate interactions.

M Klagsbrun1.   

Abstract

The interactions of basic fibroblast growth factor (bFGF) with heparin-like molecules appear to be biologically significant. Heparin and heparan sulfate protect bFGF from inactivation by heat, extreme pH and protease degradation. At the cellular level, bFGF binds to heparan sulfate on the cell surface. Cell surface heparan sulfate proteoglycans (HSPG) constitute relatively low affinity binding sites for bFGF. Furthermore, binding of bFGF to cell surface HSPG is necessary for its binding to high affinity FGF receptors and for its mitogenic activity. Thus, bFGF activity requires a dual receptor system composed of a classical protein-type tyrosine kinase receptor and a lower affinity glycosaminoglycan-type receptor. In addition, bFGF is bound to HSPG in the extracellular matrix (ECM). It has been suggested that bFGF may be sequestered in ECM as part of a stable insoluble FGF-HSPG complex from which it is released by specific enzymatic mechanisms when needed for mitogenic activity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1378313

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  24 in total

1.  Novel glycosaminoglycan biosynthetic inhibitors affect tumor-associated angiogenesis.

Authors:  Karthik Raman; Masayuki Ninomiya; Thao Kim Nu Nguyen; Yasuhiro Tsuzuki; Mamoru Koketsu; Balagurunathan Kuberan
Journal:  Biochem Biophys Res Commun       Date:  2010-11-19       Impact factor: 3.575

2.  A quantitative investigation of immunocytochemically stained blood vessels in normal, benign, premalignant and malignant human oral cheek epithelium.

Authors:  Y Jin; G L Tipoe; F H White; L Yang
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

3.  Heparin and heparan sulphate protect basic fibroblast growth factor from non-enzymic glycosylation.

Authors:  N N Nissen; R Shankar; R L Gamelli; A Singh; L A DiPietro
Journal:  Biochem J       Date:  1999-03-15       Impact factor: 3.857

4.  Capturing the stem cell paracrine effect using heparin-presenting nanofibres to treat cardiovascular diseases.

Authors:  Matthew J Webber; Xiaoqiang Han; S N Prasanna Murthy; Kanya Rajangam; Samuel I Stupp; Jon W Lomasney
Journal:  J Tissue Eng Regen Med       Date:  2010-12       Impact factor: 3.963

5.  Expression of autoactivated stromelysin-1 in mammary glands of transgenic mice leads to a reactive stroma during early development.

Authors:  N Thomasset; A Lochter; C J Sympson; L R Lund; D R Williams; O Behrendtsen; Z Werb; M J Bissell
Journal:  Am J Pathol       Date:  1998-08       Impact factor: 4.307

6.  In vitro inhibition of the actions of basic FGF by a novel 16 amino acid peptide.

Authors:  I Cosic; A E Drummond; J R Underwood; M T Hearn
Journal:  Mol Cell Biochem       Date:  1994-01-12       Impact factor: 3.396

Review 7.  Roles of integrins in tumor angiogenesis and lymphangiogenesis.

Authors:  Barbara Garmy-Susini; Judith A Varner
Journal:  Lymphat Res Biol       Date:  2008       Impact factor: 2.589

8.  Attenuation of fibroblast growth factor signaling by poly-N-acetyllactosamine type glycans.

Authors:  Kazuhiro Sugihara; Toshiaki K Shibata; Kayoko Takata; Takako Kimura; Naohiro Kanayama; Roy Williams; Shingo Hatakeyama; Tomoya O Akama; Chu-Wei Kuo; Kay-Hooi Khoo; Michiko N Fukuda
Journal:  FEBS Lett       Date:  2013-08-19       Impact factor: 4.124

9.  Basic fibroblast growth factor-heparan sulphate complex in the human dialysis-related amyloidosis.

Authors:  H Morita; T Shinzato; Z Cai; G David; A Mizutani; H Habuchi; M Ito; J Asai; K Isobe; H Yamada
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

Review 10.  25th anniversary article: supramolecular materials for regenerative medicine.

Authors:  Job Boekhoven; Samuel I Stupp
Journal:  Adv Mater       Date:  2014-02-04       Impact factor: 30.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.